GT Biopharma, Inc.

NASDAQ: GTBPInvestor Website →

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing innovative immuno-oncology therapies designed to harness the power of the body’s immune system to fight cancer. The company’s research is centered on its proprietary TriKE® (Tri-specific Killer Engager) platform, which activates and enhances the cancer-killing activity of natural killer (NK) immune cells. The TriKE® platform is engineered to stimulate NK cell proliferation and direct targeted immune responses against tumor cells. GT Biopharma holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies based on this technology, advancing a pipeline of next-generation immunotherapies aimed at improving treatment outcomes for patients with cancer.

Overview | GT Biopharma, Inc.

Company News|Latest News, Press and Market Commentary

No Newswire posts found

Bloomberg|News

Schwab's Sonders on the Rise of Casino Culture in Markets
US-Iran Talks Stall After Hezbollah Rejects Truce
SpaceX Seeks to Raise $75 Billion in What Could Be Biggest IPO Ever
US Adds 172,000 Jobs in May Topping All Estimates
US-Iran Talks at a Standstill as Hezbollah Rejects Truce
Ray Dalio on US Debt, AI Bubble, Bond Markets
California in Focus as Six State Hold Primaries
SpaceX Said to Target $75 Billion in IPO at $135 Per Share
Former VP Mike Pence on Conservatism, AI, Donald Trump
BofA CEO Moynihan on Affordability, Lending and AI Spending
Fed Beige Book Shows Steady Employment, Higher Inflation
Bloomberg Global Credit Forum | Live From New York

CNBC|News

CrowdStrike CEO George Kurtz goes one-on-one with Jim Cramer
Jim Cramer: I fear SpaceX is losing so much money the stock could be a drain for some time
Palo Alto Networks CEO Nikesh Arora goes one-on-on with Jim Cramer
FedEx Freight CEO John Smith sits down with Jim Cramer
I wonder if we will say this is the era when Dell took over the computer space, says Jim Cramer
Applied Materials CEO Gary Dickerson: This is the greatest time in the history of our industry
Salesforce CEO Marc Benioff goes one-on-one with Jim Cramer
Jim Cramer breaks down the numbers behind SpaceX's valuation
Databricks CEO Ali Ghodsi: AI doesn't have an intelligence problem. It has a context problem
Jim Cramer on playing the waiting game in the market
FedEx CEO responds to Amazon Supply Chain Services announcement
The American consumer is unbelievably resilient, says Affirm CEO

Market Chart

Spotrate

GT Biopharma, Inc.

ExchangeNASDAQ
SymbolNASDAQ: GTBP

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing innovative immuno-oncology therapies designed to harness the power of the body’s immune system to fight cancer. The company’s research is centered on its proprietary TriKE® (Tri-specific Killer Engager) platform, which activates and enhances the cancer-killing activity of natural killer (NK) immune cells.The TriKE® platform is engineered to stimulate NK cell proliferation and direct targeted immune responses against tumor cells. GT Biopharma holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies based on this technology, advancing a pipeline of next-generation immunotherapies aimed at improving treatment outcomes for patients with cancer

Market Summary

1

Biotechnology sector driven by innovation in therapeutics and life sciences.

2

Strong institutional interest due to high-growth and breakthrough potential.

3

Pipeline-driven valuations with catalysts tied to clinical milestones.

4

Advancements in immunotherapy and precision medicine shaping sector growth.

Industry Insights

1

Biotechnology companies play a critical role in advancing global healthcare innovation.

2

Firms focus on developing new therapeutics, diagnostics, and biomedical technologies.

3

The sector is driven by breakthroughs in immunotherapy and precision medicine.

4

Clinical trial results and regulatory approvals act as major valuation catalysts.

5

Institutional capital is attracted by long-term growth and innovation potential.

6

Biotech sits at the forefront of next-generation medical and scientific advancement.

Industry Leaders

Eli Lilly

LLY

Global pharmaceutical leader in obesity, diabetes, and oncology.

Novo Nordisk

NVO

Leader in diabetes care and GLP-1 therapies.

Johnson & Johnson

JNJ

Diversified healthcare and pharmaceutical giant.

Merck & Co.

MRK

Oncology and vaccine powerhouse (Keytruda).

AbbVie

ABBV

Immunology and oncology-focused biopharma company.

Amgen

AMGN

Biotech leader in biologics and biosimilars.

Gilead Sciences

GILD

Antiviral and oncology-focused biotech.

Regeneron Pharmaceuticals

REGN

Innovative biotech in immunology and eye care.

Vertex Pharmaceuticals

VRTX

Leader in cystic fibrosis and gene-based therapies.

Moderna

MRNA

mRNA platform biotechnology company.

Sector Stocks

Replimune Group

REPL

Oncolytic immunotherapy development.

ORIC Pharmaceuticals

ORIC

Targeted cancer therapies.

Anixa Biosciences

ANIX

Cancer immunotherapy and vaccines.

ImmunityBio

IBRX

Cell-based immunotherapy platform.

Iovance Biotherapeutics

IOVA

Tumor-infiltrating lymphocyte therapies.

Precigen

PGEN

Gene and cell therapy platform.

Exelixis

EXEL

Cancer-focused biotech therapeutics.

Incyte

INCY

Oncology and inflammation treatments.

BridgeBio Pharma

BBIO

Genetic disease therapeutics.

Krystal Biotech

KRYS

Gene therapy innovation.

Kymera Therapeutics

KYMR

Targeted protein degradation platform.

Moderna

MRNA

mRNA-based therapeutics and vaccines.

Regeneron Pharmaceuticals

REGN

Biologic drug development leader.

Vertex Pharmaceuticals

VRTX

Genetic disease therapies.

BioMarin Pharmaceutical

BMRN

Rare disease treatments.

Alnylam Pharmaceuticals

ALNY

RNA interference therapeutics.

Trading Platforms